Redhill Biopharma (NASDAQ:RDHL) Stock Price Crosses Below Two Hundred Day Moving Average – Here’s What Happened

Posted by Stanley Muller on Jul 10th, 2026

Redhill Biopharma Ltd. (NASDAQ:RDHL – Get Free Report)’s share price crossed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $0.98 and traded as low as $0.6850. Redhill Biopharma shares last traded at $0.7015, with a volume of 55,612 shares trading hands.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings raised shares of Redhill Biopharma from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, May 6th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Redhill Biopharma currently has an average rating of “Sell”.

View Our Latest Report on RDHL

Redhill Biopharma Trading Down 1.2%

The company has a market cap of $3.64 million, a P/E ratio of 0.00 and a beta of 4.98. The business has a 50 day moving average price of $0.92 and a 200-day moving average price of $0.98.

Institutional Inflows and Outflows

An institutional investor recently raised its stake in Redhill Biopharma stock. Gagnon Securities LLC boosted its position in Redhill Biopharma Ltd. (NASDAQ:RDHL – Free Report) by 383.1% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 86,102 shares of the biotechnology company’s stock after purchasing an additional 68,280 shares during the quarter. Gagnon Securities LLC owned about 1.68% of Redhill Biopharma worth $89,000 at the end of the most recent reporting period. 7.20% of the stock is currently owned by institutional investors and hedge funds.

Redhill Biopharma Company Profile

(Get Free Report)

RedHill Biopharma Ltd. is a specialty biopharmaceutical company focused on the development and commercialization of proprietary, orally-administered small molecules for the treatment of inflammatory, gastrointestinal and oncology indications. Founded in 2009 and headquartered in Tel Aviv, Israel, RedHill is publicly traded on the Nasdaq under the symbol RDHL. The company’s strategy centers on in-licensing late-stage clinical candidates and advancing them through regulatory review toward global commercialization.

RedHill’s lead marketed product, Talicia® (formerly RHB-105), is an FDA-approved, three-drug treatment for Helicobacter pylori infection, co-commercialized in the United States through a partnership with Bausch Health.